wasa Thanks for the kind words. For what it's worth (and it may...

wasa

Thanks for the kind words.

For what it's worth (and it may be worth very little), I'm thinking that a "short timeframe" could be any time within the next 6 months, given the company's persistent use of tantalising phrase sets such as:being in "advanced discussions with potential licensees of Progenza rights for disease specific indications in Japan" (24/5/17 announcement); and, now having positive clinical data to support "near term Progenza licensing opportunities in Japan"(22/5/17 announcement).

zeno9